• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Dermatitis - Pipeline Review, H1 2012 Product Image

Dermatitis - Pipeline Review, H1 2012

  • Published: March 2012
  • 211 pages
  • Global Markets Direct

Dermatitis – Pipeline Review, H1 2012

Summary

Global Markets Direct’s, 'Dermatitis - Pipeline Review, H1 2012', provides an overview of the Dermatitis therapeutic pipeline. This report provides information on the therapeutic development for Dermatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Dermatitis. 'Dermatitis - Pipeline Review, H1 2012' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Dermatitis.
- A review of the Dermatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific READ MORE >



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Dermatitis Overview
Therapeutics Development
An Overview of Pipeline Products for Dermatitis
Dermatitis Therapeutics under Development by Companies
Dermatitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Dermatitis Therapeutics – Products under Development by Companies
Dermatitis Therapeutics – Products under Investigation by Universities/Institutes
Companies Involved in Dermatitis Therapeutics Development
Johnson & Johnson
Bayer HealthCare AG
Amgen Inc.
GlaxoSmithKline plc
Daiichi Sankyo Company, Ltd
Novartis AG
Dong-A Pharmaceutical Co., Ltd.
Eisai Co., Ltd.
Galderma S.A.
LEO Pharma A/S
Manhattan Pharmaceuticals, Inc.
Almirall, S.A.
Basilea Pharmaceutica Ltd.
NicOx SA
Nuvo Research Inc.
Regeneron Pharmaceuticals, Inc.
Hanall Pharmaceutical Co., Ltd.
AnGes MG, Inc.
Biotie Therapies Corp.
Provectus Pharmaceuticals, Inc.
Summit Corporation plc
Proximagen Neuroscience plc.
R-Tech Ueno, Ltd.
Fougera
Paloma Pharmaceuticals, Inc.
Asubio Pharmaceuticals, Inc.
Palau Pharma S.A
Respiratorius AB
MIKA Pharma GmbH
CREABILIS Therapeutics S.r.l.
Anacor Pharmaceuticals, Inc.
JADO Technologies GmbH.
IMMD Inc.
Circassia Holdings Ltd.
Hawthorn Pharmaceuticals, Inc.
Oxagen Limited
Melior Discovery, Inc.
NovImmune SA
SARcode Corporation
Welichem Biotech Inc.
Cutanea Life Sciences
Action Pharma A/S
SWITCH Biotech LLC
Aerovance, Inc.
Morria Biopharmaceuticals Plc
Maruho Co.,Ltd.
Pharis Biotec GmbH
Kemin Industries, Inc.
Interprotein Corporation
Mimetica Pty Ltd.
Celtic Pharmaceutical Holdings L.P.
Immune Technologies and Medicine
Mantecorp Industria Quimica e Farmaceutica Ltda
EMS S.A.
Dermatitis – Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
GW870086 - Drug Profile
MK52 - Drug Profile
MK51 - Drug Profile
MK50 - Drug Profile
SUN13834 - Drug Profile
Steroid DuraPeel - Drug Profile
NCX 1047 - Drug Profile
Toctino - Drug Profile
NI-0801 - Drug Profile
DD-1 - Drug Profile
AMG 157 - Drug Profile
CT327 - Drug Profile
CLS001 - Drug Profile
PH-10 - Drug Profile
DPK-060 - Drug Profile
HL009 - Drug Profile
HL009 - Drug Profile
LEO 29102 - Drug Profile
Ronomilast - Drug Profile
Aeroderm - Drug Profile
MRX6 - Drug Profile
DNK333 - Drug Profile
JNJ-39758979 - Drug Profile
IMD-0354 - Drug Profile
WBI-1001 - Drug Profile
ProtoCure Emulsion Cream - Drug Profile
CD 2027 - Drug Profile
AN2898 - Drug Profile
LAS41004 - Drug Profile
SMT D002 - Drug Profile
J607Y - Drug Profile
J775Y - Drug Profile
NFkappaB Decoy Oligodeoxynucleotide - Drug Profile
Mapracorat - Drug Profile
J555Y - Drug Profile
AP405 - Drug Profile
DA-9102 - Drug Profile
AN2728 - Drug Profile
IgE Inhibitor - Drug Profile
Zinc Regulator - Drug Profile
SWT01113 - Drug Profile
SWT05141 - Drug Profile
PAR-2 Program - Drug Profile
RTU-1096 - Drug Profile
Efalizumab - Drug Profile
5-Methoxypsoralen + Photochemotherapy - Drug Profile
Miltefosine - Drug Profile
LAS41003 - Drug Profile
LAS41002 - Drug Profile
Kineret - Drug Profile
VAL-002 - Drug Profile
PETIR drugs - Drug Profile
Dexamethasone + Clemastine Fumarate - Drug Profile
Ipomea Pes-Caprae Ointment - Drug Profile
Prednisolone Acetate - Drug Profile
REGN668 - Drug Profile
PAP-1 - Drug Profile
Curcumin C3 Complex - Drug Profile
Hydrocortison - Drug Profile
E6005 - Drug Profile
haw S13 - Drug Profile
M516102 - Drug Profile
Product 0405 - Drug Profile
Palomid 529 Topical - Drug Profile
UR-65318 - Drug Profile
MTC896 - Drug Profile
DM107 - Drug Profile
LEKTI-6 - Drug Profile
Clemastine fumarate + Dexamethasone - Drug Profile
REGN846 - Drug Profile
Xolair - Drug Profile
TA-7906 - Drug Profile
HO/07/09 - Drug Profile
Clobetasol Propionate + Ketoconazole - Drug Profile
MLR 1130 - Drug Profile
CCRL2 Program - Drug Profile
SIG1311 - Drug Profile
AIK1 - Drug Profile
BPR277 - Drug Profile
Polymyxin B Sulfate + Prednisolone + Benzocaine + Clioquinol - Drug Profile
RS-1269 - Drug Profile
RESP-5000 - Drug Profile
Dermatitis Therapeutics – Drug Profile Updates
Dermatitis Therapeutics – Discontinued Products
Dermatitis Therapeutics - Dormant Products
Dermatitis – Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Dermatitis, H1 2012
Products under Development for Dermatitis – Comparative Analysis, H1 2012
Number of Products under Development by Companies, H1 2012
Number of Products under Development by Companies, H1 2012 (Contd..1)
Number of Products under Development by Companies, H1 2012 (Contd..2)
Number of Products under Development by Companies, H1 2012 (Contd..3)
Number of Products under Development by Companies, H1 2012 (Contd..4)
Number of Products under Investigation by Universities/Institutes, H1 2012
Comparative Analysis by Late Stage Development, H1 2012
Comparative Analysis by Mid Clinical Stage Development, H1 2012
Comparative Analysis by Early Clinical Stage Development, H1 2012
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H1 2012
Products under Development by Companies, H1 2012
Products under Development by Companies, H1 2012 (Contd..1)
Products under Development by Companies, H1 2012 (Contd..2)
Products under Development by Companies, H1 2012 (Contd..3)
Products under Development by Companies, H1 2012 (Contd..4)
Products under Investigation by Universities/Institutes, H1 2012
Johnson & Johnson, H1 2012
Bayer HealthCare AG, H1 2012
Amgen Inc., H1 2012
GlaxoSmithKline plc, H1 2012
Daiichi Sankyo Company, Ltd, H1 2012
Novartis AG, H1 2012
Dong-A Pharmaceutical Co., Ltd., H1 2012
Eisai Co., Ltd., H1 2012
Galderma S.A., H1 2012
LEO Pharma A/S, H1 2012
Manhattan Pharmaceuticals, Inc., H1 2012
Almirall, S.A., H1 2012
Basilea Pharmaceutica Ltd., H1 2012
NicOx SA, H1 2012
Nuvo Research Inc., H1 2012
Regeneron Pharmaceuticals, Inc., H1 2012
Hanall Pharmaceutical Co., Ltd., H1 2012
AnGes MG, Inc., H1 2012
Biotie Therapies Corp., H1 2012
Provectus Pharmaceuticals, Inc., H1 2012
Summit Corporation plc, H1 2012
Proximagen Neuroscience plc., H1 2012
R-Tech Ueno, Ltd., H1 2012
Fougera, H1 2012
Paloma Pharmaceuticals, Inc., H1 2012
Asubio Pharmaceuticals, Inc., H1 2012
Palau Pharma S.A, H1 2012
Respiratorius AB, H1 2012
MIKA Pharma GmbH, H1 2012
CREABILIS Therapeutics S.r.l., H1 2012
Anacor Pharmaceuticals, Inc., H1 2012
JADO Technologies GmbH., H1 2012
IMMD Inc., H1 2012
Circassia Holdings Ltd., H1 2012
Hawthorn Pharmaceuticals, Inc., H1 2012
Oxagen Limited, H1 2012
Melior Discovery, Inc., H1 2012
NovImmune SA, H1 2012
SARcode Corporation, H1 2012
Welichem Biotech Inc., H1 2012
Cutanea Life Sciences, H1 2012
Action Pharma A/S, H1 2012
SWITCH Biotech LLC, H1 2012
Aerovance, Inc., H1 2012
Morria Biopharmaceuticals Plc, H1 2012
Maruho Co.,Ltd., H1 2012
Pharis Biotec GmbH, H1 2012
Kemin Industries, Inc., H1 2012
Interprotein Corporation, H1 2012
Mimetica Pty Ltd., H1 2012
Celtic Pharmaceutical Holdings L.P., H1 2012
Immune Technologies and Medicine, H1 2012
Mantecorp Industria Quimica e Farmaceutica Ltda, H1 2012
EMS S.A., H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Stage and Molecule Type, H1 2012
Dermatitis Therapeutics – Drug Profile Updates
Dermatitis Therapeutics – Discontinued Products
Dermatitis Therapeutics – Dormant Products
Dermatitis Therapeutics – Dormant Products (Contd..1)
Dermatitis Therapeutics – Dormant Products (Contd..2)
Dermatitis Therapeutics – Dormant Products (Contd..3)
Dermatitis Therapeutics – Dormant Products (Contd..4)

List of Figures
Number of Products under Development for Dermatitis, H1 2012
Products under Development for Dermatitis – Comparative Analysis, H1 2012
Products under Development by Companies, H1 2012
Products under Investigation by Universities/Institutes, H1 2012
Late Stage Products, H1 2012
Mid Clinical Stage Products, H1 2012
Early Clinical Stage Products, H1 2012
Discovery and Pre-Clinical Stage Products, H1 2012
Assessment by Monotherapy Products, H1 2012
Assessment by Combination Products, H1 2012
Assessment by Route of Administration, H1 2012
Assessment by Stage and Route of Administration, H1 2012
Assessment by Molecule Type, H1 2012
Assessment by Stage and Molecule Type, H1 2012

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos